Virologic

[Luna]

VLGC macht ein Fass auf :)

http://a676.g.akamaitech.net/f/676/838/1h/nasdaq.com/logos/vlgc.gif
VLGC
WKN 936848

ViroLogic mit Sitz in South San Francisco entwickelt, vermarktet und vertreibt Produkte zur gesteuerten und verbesserten Behandlung von Viruserkrankungen. Das Unternehmen hat mit PhenoSense eine eigene Technologie zur direkten Messung der Einwirkung von genetischen Veränderungen auf Resistenz von Medikamenten entwickelt und nutzt diese Informationen zur Steuerung von Therapien. PhenoSense wurde für Testverfahren zur Resistenz von Medikamenten in Viren genutzt, die ernste Viruserkrankungen wie AIDS, Hepatitis B und Hepatitis C verursachen. Das erste Produkt des Unternehmens, PhenoSense HIV, ist ein Test, der direkt und quantitativ die Resistenz des HIV-Virus eines Patienten auf Antivirenmedikamente misst. Die Ergebnisse helfen den behandelnden Ärzten bei der Auswahl geeigneter Medikamente für ihre HIV-Patienten. ViroLogic entwickelt auch PhenoSense-Produkte für andere ernste Viruserkrankungen und sammelt die Testergebnisse und relevante klinische Daten in einer interaktiven Datenbank, die das Unternehmen für behandelnde Ärzte zur Nutzung verbesserter Therapieverfahren zugänglich machen möchte.

Gerade vor dem Hintergrund der vermehrten Gefahr durch biologische Waffen gewinnen diese Testsysteme im Kampf gegen den Bio-Terrorismus immens an Bedeutung. Korrupte Wissenschaftler sind in der Lage, Viren gezielt so zu manipulieren, dass sie gegen herkömmliche Heilmethoden resistent sind. Behandelnde Ärzte haben dann nur eine Chance, die richtige Behandlungsmethode zu finden. ViroLogic trifft mit seinen fortschrittlichen, hochpräzisen und individuell zugeschnittenen Testverfahren hier auf einen riesigen Bedarf.

Bei der Produktentwicklung besitzt ViroLogic einen entscheidenden Vorteil gegenüber anderen Biotech-Unternehmen: Die Testsysteme fallen in den Bereich der Medizintechnik und müssen daher nicht durch den sonst üblichen langwierigen Zulassungsprozess gehen. Diese Tatsache spart dem Unternehmen viel Zeit bei seiner Forschung.

http://chart.bigcharts.com/bc3/intchart/frames/chart.asp?symb=VLGC&compidx=aaaaa%3A0&comp=nbi&ma=0&maval=9&uf=0&lf=1&lf2=4&lf3=0&type=64&size=2&state=8&sid=175146&style=380&time=8&freq=1&nosettings=1&rand=7271&mocktick=1
Als kleine Depotbeimischung geeignet

Q-2 Zahlen
Revenue 6.7 Mio.USD
Net income -5.5 Mio. USD

http://www.quicken.com/images/graphs/?typ=li&wid=475&hei=220&dat=900000+1900000+1900000+2800000+3100000+4800000 +4400000+6000000+5700000+6700000+-5500000+-5000000+-5900000+-6800000+-7000000+-5900000+-6600000+-6700000+-6100000+-5500000+-20900000+-4600000+-5800000+-6200000+-6300000+-5100000+-8200000+-6300000+-8400000+-2147483648&row=3&col=10&tim=&tis=&rwl=Revenue+Net%20Income+Cash%20Flow&cll=Q1/'00+Q2/'00+Q3/'00+Q4/'00+Q1/'01+Q2/'01+Q3/'01+Q4/'01+Q1/'02+Q2/'02&gdf=gdonb&ldf=mc&alt=d

Latest News:

ViroLogic Announces Data on Increase in HIV Drug Resistance Published In New England Journal of Medicine

Updated: Thursday, August 8, 2002 07:31 AM ET
Results Strongly Supports Resistance Testing for Newly-Infected


SOUTH SAN FRANCISCO, Calif., Aug. 8 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC, news, msgs) announced today that the spread of drug-resistant HIV has accelerated rapidly over the last several years according to research using its technology and published in this week's issue of The New England Journal of Medicine. Drug-resistant viruses were evaluated utilizing the Company's PhenoSense(TM) HIV drug resistance technology.

The researchers concluded that the study results strongly support the use of resistance testing in the initial selection and management of therapy in all newly infected HIV patients, since there is no way to identify which patients might be infected with resistant virus without testing.

"We are excited that ViroLogic's technology is so prominently featured in one the world's leading medical journals, demonstrating its growing importance and impact," said Bill Young, ViroLogic's Chairman and Chief Executive Officer. "Our sales representatives will use this publication to help continue to increase the use of our resistance tests."

[Ca$hmandt]

ViroLogic Data Support Widespread Clinical Utility of Drug Resistance Testing in HIV Treatment

- 13 Relevant Studies Presented at 12th International HIV Drug Resistance Workshop -

CABO DEL SOL, Mexico, June 11 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC - News) announced today the presentation of 13 studies utilizing its HIV drug resistance technologies by Company scientists and their collaborators at the 12th International HIV Drug Resistance Workshop being held here this week. These studies demonstrate the broad applicability of ViroLogic's platform technology for the assessment of antiretroviral drug resistance and viral replication in diverse clinical and research settings, aiding in improved treatment of HIV infection.

Through collaborations with leading investigators from academia, government and industry, we continue to define and broaden the clinical utility of ViroLogic's technology, improving the clinician's ability to optimize management of antiretroviral therapy for their patients," said Michael P. Bates, M.D., ViroLogic's Senior Director of Clinical Research. "Additionally, we continue to realize the value of our database to further enhance assessments of antiretroviral resistance in the clinical setting and assist our pharmaceutical colleagues in developing novel drugs to treat HIV infection."

The 13 presentations describe a wide range of studies undertaken by scientists at ViroLogic, both independently and in collaboration with academic and pharmaceutical company scientists. The pharmaceutical collaborations applied ViroLogic's tools and resources, including the Company's virus specimen library, towards the identification and development of novel drug candidates, such as viral entry inhibitors. In addition, several collaborators are presenting evidence demonstrating the use of ViroLogic's database to help validate resistance and cross resistance profiles for new drugs, evaluate replication capacity and develop improved algorithms to predict infectivity and resistance.

Two notable collaborative studies presented at the meeting highlight the diverse applicability of ViroLogic's technologies in distinct HIV populations.

Dr. Susan J. Little and her colleagues at U.C. San Diego applied ViroLogic's PhenoSense(TM), GeneSeq(TM) and Replication Capacity(TM) assays to assess the persistence of transmitted drug resistant variants in the absence of antiretroviral drug treatment among subjects with primary HIV infection. The study demonstrated that drug-resistant viruses can persist for months to years after infection. Transmitted resistance to three classes of antiretroviral drugs demonstrated durable persistence with strong implications for the management of HIV infected individuals who have yet to be treated with antiretroviral drugs.

In the treatment-experienced patient population, sustained immunologic benefits in the absence of fully suppressed viral replication may be explained by diminished levels of T-cell activation. Dr. Peter W. Hunt and colleagues at U.C. San Francisco focused on the relationship between T-cell activation, viral replication capacity and drug resistance in patients undergoing partial or full treatment interruptions. They concluded that in patients with incomplete suppression of viral replication, maintenance of the drug-resistant phenotype and the suppression of viral load below pre-therapy levels are necessary for the continued reduction in T-cell activation and preservation of immunologic benefit in these patients. These data suggest that drug resistant viruses with reduced replication capacity produce less rapid destruction of immune function in patients, supporting the use of phenotypic drug susceptibility and replication capacity testing to manage patients experiencing treatment failure.

"The presentations at this meeting featuring our technology demonstrate further advantages of resistance testing in the management of HIV patients, including those individuals who have not received prior antiretroviral treatment," said Christos J. Petropoulos, Ph.D., Vice President of Research and Development at ViroLogic. "Our strong presence at this prestigious scientific meeting demonstrates ViroLogic's leadership in drug resistance testing and how our technology can be applied to enhance HIV patient management and advance drug development."

[Ca$hmandt]

Am 5. August gibs neue Zahlen bei VLGC:




ViroLogic Announces Second Quarter 2003 Earnings Conference Call


SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--July 22, 2003--ViroLogic, Inc. (Nasdaq:VLGC - News) announced that it will hold a conference call on Tuesday, August 5, 2003 at 5:00 p.m. EDT to discuss second quarter earnings results. The call will be hosted by Mr. Bill Young, Chairman & CEO of ViroLogic, Inc.
To participate in the teleconference please call (800) 884-5695 fifteen minutes before the conference begins. International callers please dial (617) 786-2960.

The call will also be webcast live at www.virologic.com. Please see web site for details.

[sterntaler]

Bei VLGC habe ich den vorbörslichen Kurs heute schon bei etwa 20 Prozent höher gesehen als gestern (IB-data vorhin: $ 1.39/1.40), der Grund sind wohl gute
Nachrichten (http://news.nasdaq.com/news/newsStory.aspx?&logopath=http%3A%2F%2Fcontent%2Enasdaq%2Ecom%2Flog os%2FVLGC%2EGIF&pageName=Company+News&selected=VLGC&HeadLineReturnPage=http%3A%2F%2Fwww%2Enasdaq%2Ecom %2F%2Fasp%2Fquotes%5Fnews%2Easp&HeadlineTargetFrame=_top&StoryReturnPage=http%3A%2F%2Fwww%2Enasdaq%2Ecom%2F %2Fasp%2Fquotes%5Fnews%2Easp&Consumer=NDQ&StoryTargetFrame=_top&cpath=20030731%5C200307310731CTXPRN39100561%2Ehtm&symbol=VLGC%60&coname=ViroLogic%2C+Inc%2E&market=Nasdaq%2DNM),
denen zufolge das Nationale Institut für Allergie- und Infektionskrankheiten der Firma Forschungs- und Entwicklungsgelder in Höhe von über 3 Mio. $ über die nächsten drei Jahre verteilt zukommen lassen will (hoffe, ich hab's richtig).
http://chart.bigcharts.com/bc3/quickchart/chart.asp?symb=vlgc&compidx=aaaaa%3A0&ma=0&maval=9&uf=0&lf=1&lf2=0&lf3=0&type=4&size=2&state=13&sid=175146&style=340&time=6&freq=1&nosettings=1&rand=6058&mocktick=1&rand=7686

[NYC]

thanks @sterntaler, habe ich im pre-market übersehen!

[Ca$hmandt]

jetzt nur noch 1.30!

[NYC]

jetzt nur noch 1.30!
Kopf hoch, die knacken wir noch.
1/3 des gestrigen Volumen sind bereits im pre-market umgesetzt worden. :( ;)

[sterntaler]

Ist ja eine unglaubliche Rally bei dollen Umsätzen ... :rolleyes: ... mir ist schon ganz schwindelig! :hmpf:

(...) die knacken wir noch. jo: geknackt! Aber nach unten hin ... :eek: http://www.smiliemania.de/smilie.php?smile_ID=292
Ja, @NYC, es war wohl vorbörslich schon alles gelaufen !?! http://www.smiliemania.de/smilie.php?smile_ID=107
Die Verkäuferseite dominiert jetzt sehr stark (Island).
Ich glaub',http://www.kurts-smilies.de/shuffle.gif ich geh ... http://www.kurts-smilies.de/schleich.gif da mal wieder 'raus ...

[Luna]

VLGC) today reported financial results for the second quarter and six months ended June 30, 2003.

Revenue $8.0 million for the second quarter of 2003, an increase of 19 percent over revenue of $6.7 million for the second quarter of 2002.
Net loss for the second quarter of 2003 was $2.2 million, or $0.07 per common share, compared to a net loss of $5.5 million, or $0.22 per common share, for the same period in 2002.

Nachbörslich leicht höher bei USD 1.33

[reeneex]

ViroLogic Added to the NASDAQ Biotechnology Index
Friday May 20, 5:16 pm ET

SOUTH SAN FRANCISCO, Calif., May 20 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC - News) announced today that it will be added to the NASDAQ Biotechnology Index® (Nasdaq: NBI - News) effective with the market open on May 23, 2005.
All securities are classified according to the FTSE Global Classification System(TM) as biotechnology or pharmaceutical. Index eligibility criteria include listing on the NASDAQ National Market® and meeting minimum requirements for market value, average daily share volume and seasoning as a public company.

The Index is ranked on a semi-annual basis in May and November. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit http://www.NASDAQ.com .

About ViroLogic

ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biotechnology and pharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at www.virologic.com.

FORWARD LOOKING STATEMENTS

Certain statements in this press release are forward-looking, including statements regarding the addition of ViroLogic to the NASDAQ Biotechnology Index. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward- looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties relating to the development of future products; the performance of our products; our ability to successfully conduct clinical studies and the results obtained from those studies; whether larger confirmatory clinical studies will confirm the results of initial studies; whether larger studies involving tumor samples will yield favorable results regarding the predictive capability of eTag assays for responsiveness to cancer drugs; our ability to establish reliable, high-volume operations at commercially reasonable costs; our ability to introduce a product commercially in 2006; our ability to successfully integrate the operations of ACLARA into our operations; competition from larger more established diagnostic providers; actual market acceptance of our products and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the level of demand for our products; the timing and ultimate size of pharmaceutical company clinical trials; whether payors will authorize reimbursement for our products; whether the FDA or any other agency will seek to regulate ViroLogic's in house clinical laboratory testing; our ability to comply with FDA regulations in order to establish and maintain diagnostic kit manufacturing operations; whether we will encounter problems or delays in establishing and validating eTag assays within our clinical laboratory; whether we will encounter problems or delays in automating our processes or expanding our capacity; whether the intellectual property underlying the Company's technology is adequate; whether we may be deemed to infringe on the intellectual property of others and whether licenses to third party technology will be available; whether ViroLogic is able to build brand loyalty and expand revenues; the potential impact of any payments under the CVRs on our common stock and capital resources; and whether ViroLogic will be able to raise sufficient capital when required. For a discussion of other factors that may cause ViroLogic's actual events to differ from those projected, please refer to the Company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.
--------------------------------------------------------------------------------
Source: ViroLogic, Inc.


Und Noch mehr Info.
http://biz.yahoo.com/prnews/050520/sff044.html?.v=8

Und ich werde jetzt da einsteigen und abwarten. :rolleyes: